[Immunity against tick borne encephalitis virus (TBE) in population of forest workers in Bialowieza].
In Poland, 200 cases of tick borne encephalitis are annually registered. It is about half of all registered cases of viral encephalitis. Immunity acquired after vaccination with TBE inactivated vaccine persists defined time dependent on number of dose of vaccine and individual features of vaccinated person. The aim of this paper was to determine the frequency of IgG antibodies against TBE virus among forestry workers from Białowieza National Park with regard to information about vaccination against TBE virus. In the group of 59 persons vaccinated against TBE virus, 54 (91.5%) had IgG antibodies against TBE virus. In the group of 32 persons (non-vaccinated or for whom the information about vaccination was not given) 26 (81.3%) were seropositive. Relationships between VE value (determining level of antibodies), age and period passed from the last dose of vaccination were analysed. Taken to account the most disadvantageous circumstances (age = 60, regression intercept minus two standard deviation) antibodies level of VE = 11 (lower limit of positive result) remains for 2,72 years from last dose of vaccine against TBE virus. This result confirm recommendation about necessity to use of complementary dose within 3-5 years, at the same time it should be considered recommendation of necessity ofrevaccination persons 60 years old or above as frequently as every 3 years.
Siennicka
Joanna
J
Zakład Wirusologii, Narodowy Instytut Zdrowia Publicznego - PZH w Warszawie. jsiennicka@pzh.gov.pl
Trzcińska
Agnieszka
A
Gut
Włodzimierz
W
D000328:Adult; D000914:Antibodies, Viral / Q000097:blood*; D004669:Encephalitis Viruses, Tick-Borne / Q000276:immunology*; D004675:Encephalitis, Tick-Borne / Q000453:epidemiology / Q000276:immunology* / Q000517:prevention & control; D004784:Environmental Monitoring / Q000706:statistics & numerical data*; D062665:Epidemiological Monitoring; D005260:Female; D016468:Forestry / Q000706:statistics & numerical data*; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood*; D008297:Male; D009784:Occupational Diseases / Q000276:immunology / Q000517:prevention & control; D011044:Poland / Q000453:epidemiology; D014765:Viral Vaccines / Q000276:immunology
D000914:Antibodies, Viral; D007074:Immunoglobulin G; D014765:Viral Vaccines